Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06462664
Recruiting Observational

Exploring the Impact of Monocytes in Myeloproliferative Neoplasia (EMYNEM)

NCT06462664 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Brest
Phase
Observational
Started
2024-06-01
Last updated
2024-06-17

Condition(s) studied

Myeloproliferative Neoplasm

Study summary

Impact of monocytes on Myeloproliferative Neoplasm hematopoietic stem cell growth and differentiation in vitro

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of MPN in the participating center * Over 18 yo Exclusion Criteria: * Not able to consent

Primary outcome measure(s)

  • Proliferation and differentiation of hematopoitic stem/progenitor cells — 2 years

Trial sites (1)

FacilityCityRegionStatus
Chu Brest Brest France Recruiting

More University Hospital, Brest trials in France

Recurrence of Thromboembolic Venous Disease of Atypical Location (RUSE) Active, not recruiting
Changes in the Angle of Uterine Flexion as the Bladder Fills Starting soon
Shared Decision-making Process for Unprovoked vEnous THromboEmbolism Management. (ETHER ) Recruiting
Anatomical Assessment of Orbital Contents on Imaging (EACOI) Recruiting
Patientheque in Patients With a Psychosis Recruiting

Other trials for the same condition

Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis. Recruiting
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Active, not recruiting
Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms Recruiting
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes Recruiting
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06462664 on ClinicalTrials.gov ↗ ← All trials in France